Prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks: A noninferiority phase III trial (SAKK 96/12, REDUSE).

Templeton, Arnoud J. Kantonsspital St. Gallen, St. Gallen, Switzerland
Stalder, Lukas SAKK - Swiss Group for Clinical Cancer Research, Coordinating Center, Bern, Switzerland
Bernhard, Juerg International Breast Cancer Study Group, Bern, Switzerland
Brauchli, Peter Swiss Group for Clinical Cancer Research, Bern, Switzerland
Gillessen, Silke Kantonsspital St. Gallen, St. Gallen, Switzerland
Hayoz, Stefanie Swiss Group for Clinical Cancer Research, Bern, Switzerland
Klingbiel, Dirk SAKK - Swiss Group for Clinical Cancer Research, Coordinating Center, Bern, Switzerland
Matter-Walstra, Klazieu Institute of Pharmaceutical Medicine/ECPM, University Basel, Basel, Switzerland
Thurlimann, Beat J. K. Swiss Group for Clinical Cancer Research, Bern, Switzerland
Von Moos, Roger Kantonsspital Graubünden, Chur, Switzerland

Published in:

Journal of Clinical Oncology. - American Society of Clinical Oncology (ASCO). - 2014, vol. 32, no. 15_suppl, p. TPS5095-TPS5095

Language

Open access status

closed

Identifiers

Persistent URL

https://folia.unifr.ch/global/documents/287445

Document views: 20 File downloads: